Table 4.
Translational strategies under investigation.
| Strategy | Specific approach | Mechanism/target | Clinical status | Key findings/considerations |
|---|---|---|---|---|
| Biomarker development | 30-marker microbial panel | Non-invasive early HCC diagnosis | Clinical validation | AUC 80.64% in distinguishing early HCC from non-HCC |
| Serum TMAO levels | Risk assessment | Human correlation study | Positively correlated with HCC risk | |
| Fecal microbial diversity | Disease progression monitoring | Clinical research | Increases from cirrhosis to early HCC | |
| Probiotics | Single/multi strain formulations (Lactobacillus, Bifidobacterium, etc.) | Barrier enhancement; immune modulation; metabolite production | Preclinical & early clinical | Strain-specific effects; host-dependent efficacy; 26 RCTs show reduced inflammation markers |
| Prohep (synbiotic formulation) | Promotes Prevotella/Oscillibacter; inhibits Th17; reduces tumor volume by 40% | Preclinical | Upregulates IL-10, IL-13, IL-27; inhibits VEGF-A | |
| Synbiotics (GOS, FCT) | Upregulates MUC2, TFF3, tight junction proteins; enriches beneficial bacteria | Preclinical | Increases fecal SCFA levels; downregulates inflammatory markers | |
| Fecal microbiota transplantation (FMT) | From healthy donors | Reshapes microbiome; reduces inflammation; enhances ICI response | Clinical trials ongoing | Effective in alcoholic hepatitis; improves ICI response in non responders; safety concerns (infection risk, lack of standardization) |
| From ICI responders to non-responders | Increases antigen presenting cells and tumor-infiltrating lymphocytes | Clinical case studies | Reactivates anti-tumor immunity; enriches Lachnoclostridium and Akkermansia | |
| Antibiotics | Vancomycin | Selectively reduces secondary bile acid producing microbes (Clostridium clusters XI, XIVa) | Preclinical | Inhibits obesity-induced HCC; dual effects: beneficial in suppressing carcinogenic microbes but detrimental when combined with ICI (increased mortality) |
| Antibiotic stewardship | Preservation of beneficial microbiota during cancer treatment | Clinical guideline development | Concurrent antibiotic use with ICI associated with poor prognosis (HR ~ 1.46 1.60) | |
| Dietary modulation | High dietary fiber/whole grains | SCFA production; reduces HCC risk by 17% per 10 g/day fiber | Human epidemiology (strong) | 22–31% reduction in liver cancer incidence; 56–63% reduction in chronic liver disease mortality |
| Prebiotic supplementation (e.g., GOS) | Enhances beneficial bacteria; improves barrier function | Preclinical | Context-dependent: may promote tumorigenesis under dysbiosis | |
| TLR4 antagonists | Polymyxin B; LPS-binding compounds; small molecules; thalidomide derivatives | Inhibit LPS/TLR4/MyD88/NF κB pathway | Preclinical development | Reduces chronic inflammation; potential risk of immune suppression and infection |
| FXR agonists | Obeticholic acid, GW4064 | Maintain intestinal barrier; induce FGF19 release; reduce bacterial translocation | Clinical trials | Improve liver function; prevent barrier dysfunction; reduce inflammation in cirrhosis |
| Neuro-immune modulation | Targeting microbiota brain-liver axis | GABA/5-HT modulation of HPA axis and immune responses | Conceptual framework | Emerging paradigm; requires clinical validation |
| Liver-spleen axis intervention | Integrated gut liver-spleen targeting | Address systemic inflammation and splenic immune dysfunction | Preclinical research | Th17/Treg balance; macrophage polarization; novel therapeutic target |
AUC, area under the curve; TMAO, trimethylamine N-oxide; RCT, randomized controlled trial; GOS, galacto-oligosaccharides; FCT, fermented milk with L. gasseri 505 and C. tricuspidata; MUC2, mucin 2; TFF3, trefoil factor 3; VEGF-A, vascular endothelial growth factor A; FMT, fecal microbiota transplantation; ICI, immune checkpoint inhibitor; SCFA, short-chain fatty acids; TLR4, Toll-like receptor 4; LPS, lipopolysaccharide; MyD88, myeloid differentiation primary response 88; FXR, farnesoid X receptor; FGF19, fibroblast growth factor 19; GABA, gamma-aminobutyric acid; 5-HT, serotonin; HPA, hypothalamic–pituitary–adrenal. Clinical Status: Clinical validation—tested in clinical diagnostic or observational studies; Preclinical—under investigation in cell or animal models; Clinical trials ongoing—currently being evaluated in human clinical trials; Clinical research—exploratory clinical studies; Clinical guideline development—evidence supporting clinical practice recommendations; conceptual framework—theoretical foundation requiring clinical validation. Note: HR, hazard ratio. Safety considerations and standardization protocols require further development for clinical implementation. Efficacy may vary based on patient characteristics, disease etiology, and treatment context. Summary: This table synthesizes current evidence on microbiome-targeted therapeutic strategies, ranging from established biomarkers to emerging interventions. Clinical translation requires careful consideration of safety profiles, standardization protocols, and patient-specific factors.